Many patients prescribed GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or liraglutide (Victoza, Saxenda) notice changes in their bowel habits. These medications, licensed in the UK for type 2 diabetes and weight management, commonly affect the digestive system. Gastrointestinal side effects—including diarrhoea, nausea, and altered bowel frequency—are amongst the most frequently reported reactions. Understanding why these changes occur, what to expect, and when symptoms require medical attention helps patients manage treatment effectively whilst maintaining therapeutic benefits. This article examines how GLP-1 medications influence bowel function and provides practical guidance for managing digestive symptoms.
Quick Answer: GLP-1 medications can increase bowel frequency and cause looser stools in some patients, though individual responses vary considerably.
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications prescribed for specific conditions in the UK: semaglutide (Ozempic, Trulicity) and liraglutide (Victoza) for type 2 diabetes management, while semaglutide (Wegovy) and liraglutide (Saxenda) are licensed for weight management. Understanding how these medications interact with your digestive system is essential for managing expectations and recognising normal versus concerning symptoms.
GLP-1 is a naturally occurring hormone released by cells in your small intestine after eating. It works through multiple mechanisms: stimulating insulin secretion when blood glucose levels rise, suppressing glucagon release, slowing gastric emptying, and reducing appetite through effects on the brain. When pharmaceutical GLP-1 agonists are administered, they mimic these natural effects but at higher, sustained levels.
The gastrointestinal tract contains GLP-1 receptors in various regions. When GLP-1 medications bind to these receptors, they significantly slow gastric emptying (the rate at which food leaves your stomach), particularly in early treatment. This delayed stomach emptying contributes to feelings of fullness and reduced appetite, which supports therapeutic goals. This effect on gastric emptying tends to diminish somewhat over time as the body adapts.
GLP-1 medications may also influence intestinal transit time, though the precise mechanisms are not fully understood. These combined effects on the digestive system explain why many patients experience changes in their bowel habits when starting or adjusting doses of GLP-1 medications, though individual responses vary considerably.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereGastrointestinal side effects are the most frequently reported adverse reactions to GLP-1 receptor agonists, affecting a significant proportion of patients, particularly during initial treatment or dose escalation. According to clinical trial data and post-marketing surveillance, these effects are generally dose-dependent (more common with higher doses) and tend to diminish over time as the body adapts to the medication.
Diarrhoea is one of the most common side effects, with frequencies varying by product and dose. For example, diarrhoea occurs in approximately 8-17% of patients taking Ozempic and up to 20-30% with Wegovy. The increased frequency and looser consistency of stools may result from altered gut motility and changes in intestinal fluid secretion. Some patients report passing stools more frequently than usual, whilst others notice changes primarily in consistency rather than frequency.
Nausea affects 15-40% of patients (varying by product and dose) and is often the most troublesome early symptom. This occurs due to delayed gastric emptying, which can create sensations of fullness, bloating, and queasiness. Whilst nausea doesn't directly cause increased bowel movements, it may influence dietary choices that subsequently affect stool patterns.
Vomiting is also common, reported in approximately 5-25% of patients depending on the specific medication and dose.
Constipation paradoxically affects 10-20% of patients, demonstrating that GLP-1 medications can slow bowel transit to varying degrees in different individuals. Some patients alternate between diarrhoea and constipation as their digestive system adjusts.
Other reported effects include:
Abdominal discomfort or cramping
Bloating and increased flatulence
Dyspepsia (indigestion)
Acid reflux or heartburn
Less common but important side effects include gallbladder problems (such as gallstones) and, rarely, intestinal obstruction. The severity and type of gastrointestinal symptoms vary considerably between individuals and between different GLP-1 medications. Most symptoms are mild to moderate and improve significantly within 4-8 weeks of starting treatment or after dose adjustments. The MHRA continues to monitor safety data for these medications through the Yellow Card Scheme.
If you experience increased bowel frequency or looser stools whilst taking GLP-1 medication, several practical strategies can help manage these symptoms whilst allowing you to continue benefiting from treatment. Most patients find that symptoms improve with time and appropriate self-management measures.
Dietary modifications form the cornerstone of symptom management. Consider implementing these changes gradually:
Reduce intake of high-fat foods, which are digested more slowly and may exacerbate nausea and altered bowel patterns
Limit caffeine and alcohol, both of which can stimulate bowel activity
Avoid artificial sweeteners (particularly sorbitol and mannitol), which have laxative properties
Increase soluble fibre intake through oats, bananas, and cooked vegetables to help regulate stool consistency
Eat smaller, more frequent meals rather than large portions
Stay well-hydrated, particularly if experiencing diarrhoea, to prevent dehydration
For persistent diarrhoea, oral rehydration solutions (available from pharmacies) can help maintain electrolyte balance. Bulking agents containing ispaghula may help regulate stool consistency.
Timing considerations can also prove helpful. Taking your medication at a consistent time each day is important, though the specific time of day is flexible (follow your product's instructions). Consistency helps your body adjust to the medication's effects.
Medication adjustments should always be discussed with your prescribing clinician. If symptoms are particularly troublesome, your doctor may recommend:
Slower dose escalation than standard protocols
Temporary dose reduction
Switching to a different GLP-1 agonist, as individual responses vary
Short-term use of anti-diarrhoeal medications such as loperamide for acute episodes, though this should only be done under medical supervision and avoided if you have blood in your stool, fever, or suspected infection
If you're also taking insulin or sulfonylureas, monitor your blood glucose more frequently during periods of reduced appetite or diarrhoea, as you may need dose adjustments to prevent hypoglycaemia.
Keep a symptom diary noting bowel frequency, consistency (using the NHS Bristol Stool Chart as reference), associated symptoms, and dietary intake. This information helps your healthcare team assess whether symptoms are improving, stable, or worsening, and guides management decisions. Most importantly, do not discontinue your medication without consulting your prescriber, as abrupt cessation may affect your diabetes control or weight management progress.
Whilst gastrointestinal side effects are common with GLP-1 medications, certain symptoms warrant prompt medical attention. Understanding when bowel changes represent normal adjustment versus potentially serious complications ensures appropriate and timely intervention.
Seek urgent medical attention (contact 999 or attend A&E) if you experience:
Severe, persistent abdominal pain, particularly if accompanied by fever, vomiting, or inability to pass stools or wind
Blood in your stools (red blood or black, tarry stools)
Signs of severe dehydration: extreme thirst, dark urine, dizziness, confusion, or reduced urine output
Persistent vomiting preventing fluid or medication intake
Symptoms suggesting pancreatitis: severe upper abdominal pain radiating to the back, often with nausea and vomiting (if pancreatitis is suspected, stop taking your GLP-1 medication immediately)
Right upper abdominal pain with fever, yellowing of skin/eyes, dark urine or pale stools (possible gallbladder problems)
Contact NHS 111 or your GP within 24-48 hours if:
Diarrhoea persists beyond 7 days without improvement
You're passing more than 6 loose stools daily
Bowel symptoms are significantly impacting your quality of life, work, or daily activities
You're unable to maintain adequate nutrition or hydration
You develop new symptoms such as unexplained weight loss (beyond expected therapeutic effect), persistent fever, or night sweats
Symptoms worsen rather than improve over time
Routine review is appropriate if:
Mild to moderate symptoms persist but are manageable
You're uncertain whether symptoms are medication-related
You wish to discuss dose adjustments or alternative management strategies
GLP-1 medications are associated with recognised gastrointestinal risks including pancreatitis, gallbladder disease, and rarely, intestinal obstruction. These medications can occasionally mask or delay diagnosis of other gastrointestinal conditions. If you have a personal or family history of inflammatory bowel disease, coeliac disease, or colorectal cancer, inform your prescriber, as this may influence monitoring strategies.
NICE guidance recommends regular review of patients taking GLP-1 agonists, typically every 3-6 months, to assess treatment response, side effects, and ongoing appropriateness of therapy. Use these appointments to discuss any persistent digestive symptoms, even if they seem minor, as adjustments to your treatment plan may significantly improve your experience whilst maintaining therapeutic benefits.
Report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app), which helps monitor medication safety.
Most gastrointestinal side effects, including changes in bowel frequency, are most pronounced during initial treatment or dose escalation and typically improve significantly within 4-8 weeks as your body adapts to the medication.
Short-term use of loperamide may be appropriate for acute episodes, but this should only be done under medical supervision and avoided if you have blood in your stool, fever, or suspected infection. Always consult your prescriber before taking additional medications.
Do not discontinue your medication without consulting your prescriber, as abrupt cessation may affect your diabetes control or weight management progress. Contact your GP or NHS 111 if diarrhoea persists beyond 7 days or if you're passing more than 6 loose stools daily.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
